DHB (Dihydroboldenone)

DHB — Dihydroboldenone, also known as 1-Testosterone (not to be confused with methylated oral 1-testosterone supplements) — is the 5-alpha-reduced metabolite of Boldenone. Its systematic name is 17-beta-hydroxyandrost-1-en-3-one. Where Boldenone (Equipoise) must be converted by 5-alpha reductase to reach its most androgenically active form, DHB is already in that reduced state, making it a more potent and direct-acting compound. DHB carries an anabolic rating approximately double that of testosterone with an androgenic rating roughly equivalent to testosterone, and critically, it cannot aromatize to estrogen — the 5-alpha-reduced A-ring structure is not a substrate for the aromatase enzyme.

DHB acts through classical androgen receptor binding to promote protein synthesis, nitrogen retention, and satellite cell recruitment in skeletal muscle. Its inability to aromatize means it produces zero estrogenic effects — no water retention, no gynecomastia risk, no estrogen-mediated fat deposition. Unlike its parent compound Boldenone, DHB does not significantly stimulate erythropoietin production, so the hematocrit elevation seen with Equipoise is largely absent. The compound promotes lean, dry tissue accrual with a quality and density that researchers frequently compare to Primobolan or Masteron, but with substantially greater anabolic potency per milligram.

DHB is valued for producing what researchers describe as "clean gains" — lean mass increases with no estrogenic bloating, no progestogenic water retention, and minimal androgenic side effects in non-predisposed individuals. The muscle tissue built on DHB is dense, hard, and well-retained post-cycle. It is one of the few compounds that can serve as a primary anabolic agent in a cutting protocol while still providing enough anabolic stimulus to drive new tissue growth in a caloric surplus. This versatility across dietary contexts is relatively uncommon.

This compound is suited to intermediate and advanced researchers who prioritize physique quality and health markers alongside performance outcomes. Its relatively mild side-effect profile (no estrogen, no progestin, moderate androgenicity) makes it accessible to a broad range of researchers, including those who have experienced complications with wetter or more androgenic compounds. The primary caveat is post-injection pain: DHB is known for producing significant injection site discomfort in many researchers, a consequence of the compound's low solubility in standard carrier oils and the resulting crystallization at the depot site.

DHB is typically formulated with a cypionate ester, giving it a half-life of approximately 5-7 days and supporting twice-weekly injection. Standard research doses range from 200-400mg/week. Injection site management is important — warming the oil, injecting slowly, and rotating sites diligently can mitigate PIP. DHB pairs well with a testosterone base (always required), Masteron for enhanced drying, or Primobolan for maximum lean-tissue preservation with minimal systemic stress. No AI is required for the DHB itself, though any co-administered testosterone will still aromatize and require standard estrogen management.